Sun Pharma Advanced Research Company Limited (NSE:SPARC)
138.51
+1.21 (0.88%)
Dec 12, 2025, 10:15 AM IST
NSE:SPARC Revenue
Sun Pharma Advanced Research Company had revenue of 78.60M INR in the quarter ending September 30, 2025, a decrease of -38.88%. This brings the company's revenue in the last twelve months to 595.96M, down -0.81% year-over-year. In the fiscal year ending March 31, 2025, Sun Pharma Advanced Research Company had annual revenue of 717.66M, down -5.00%.
Revenue (ttm)
595.96M
Revenue Growth
-0.81%
P/S Ratio
74.76
Revenue / Employee
1.89M
Employees
316
Market Cap
44.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 717.66M | -37.79M | -5.00% |
| Mar 31, 2024 | 755.45M | -1.63B | -68.36% |
| Mar 31, 2023 | 2.39B | 1.02B | 73.98% |
| Mar 31, 2022 | 1.37B | -1.16B | -45.74% |
| Mar 31, 2021 | 2.53B | 1.76B | 229.31% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Sun Pharma Advanced Research Company News
- 9 days ago - Sparc shares surge 27% in 2 days – Know the reason behind the rally - Business Upturn
- 9 days ago - Why are SPARC shares up 20% today; Explained - Business Upturn
- 5 weeks ago - SPARC to announce Q2 results on November 10 - Business Upturn
- 4 months ago - Sun Pharma Advanced Research Q1 Results: Net loss narrows to Rs 51.8 crore, Revenue drops 42.6% YoY - Business Upturn
- 6 months ago - SPARC shares drop nearly 20% after key drug trial fails - Business Upturn
- 6 months ago - SPARC shares fall over 13% in trade today: Details here - Business Upturn
- 9 months ago - Stock Market Today: Rajesh Exports, SCI, RHIM, SPARC, and KEC among top 5 gainers on March 20, 2025 - Business Upturn
- 1 year ago - SPARC signs binding LOI with UCSF and Tiller Therapeutics for pre-clinical oncology asset - Business Upturn